MADISON, Wis., May 21, 2021 /PRNewswire/ -- Exact Sciences
Corp. (NASDAQ: EXAS) today highlights data from one oral and
one poster presentation being featured at the 2021 Digestive
Disease Week® (DDW®) virtual annual
meeting, taking place May 21-23.
Notably, the poster shares data that incorporate real-world
patient adherence rates into a colorectal cancer (CRC)
microsimulation model. The data showed that Cologuard®
(mt-sDNA) was cost effective and provided the greatest reduction in
CRC incidence and mortality versus annual fecal immunochemical test
(FIT) and annual fecal occult blood test (FOBT) in a representative
Medicare population.
Additionally, the oral presentation reports data from the New
Hampshire Colonoscopy Registry to compare FIT and Cologuard
outcomes in clinical practice. In follow-up colonoscopies performed
after a positive stool test result, Cologuard was more likely to
predict neoplasia than FIT, largely due to an increased detection
of serrated polyps.
Colorectal cancer is the second deadliest cancer impacting both
men and women in the U.S. It's also preventable if caught
in early stages when it is more
treatable.i The disease has been on the rise in
younger adults and approximately 44 million average-risk people in
the United States remain
unscreened.ii
The abstracts are now available on the DDW
website. Included below are titles, abstract numbers, and a
summary of each abstract.
Cost-Effectiveness of Stool-Based Colorectal Cancer Screening
Using Reported Real-World Adherence Rates in a Medicare
Population
Abstract Number: Su053
The impact of real-world adherence rates on the
cost-effectiveness of specific CRC screening strategies has been
unclear. This study used the CRC-AIM microsimulation modeling
platform to estimate the cost-effectiveness of stool-based
screening strategies using test-specific, real-world adherence
data. The analysis found that Cologuard was cost effective and
demonstrated the greatest reduction in CRC incidence and mortality
versus FIT and FOBT.
The results from the analysis were also published online in
the Journal of Medical Economics.
Comparison of Colonoscopy Findings in Patients with Preceding
FIT Positive and mt-sDNA Positive Tests to Patients Having
Colonoscopy Only: Data From the New Hampshire Colonoscopy
Registry
Abstract Number: 886
There are few comparisons of FIT and Cologuard screening test
outcomes in clinical practice. Using the New Hampshire Colonoscopy
Registry (NHCR), a comprehensive statewide population-based
colonoscopy database, the diagnostic yield of colorectal neoplasia
in follow-up colonoscopies in patients with a previous positive
FIT, Cologuard, or screening colonoscopy were compared. After
follow-up colonoscopy, 1.7% of patients with a positive Cologuard
test, 1.6% of patients with positive FIT and 0.3% of patients who
underwent screening colonoscopy had adenocarcinoma/colorectal
cancer. At follow-up colonoscopy, Cologuard tests were more
likely to predict neoplasia than either FIT positivity or screening
colonoscopy, largely due to an increased yield of serrated
polyps.
Media Contact:
Cara
Connelly, cconnelly@exactsciences.com, 614-302-5622
Investor Contact:
Megan
Jones, meganjones@exactsciences.com, 608-535-8815
About Exact Sciences Corp.
A leading provider of
cancer screening and diagnostic tests, Exact Sciences relentlessly
pursues smarter answers to give people the clarity to take
life-changing action, earlier. Building on the success of Cologuard
and Oncotype® tests, Exact Sciences is investing in its
product pipeline to support patients throughout their cancer
diagnosis and treatment. Exact Sciences unites visionary
collaborators to help advance the fight against cancer. For more
information, please visit the company's website
at www.exactsciences.com, follow Exact Sciences on Twitter
@ExactSciences, or find Exact Sciences on Facebook.
Note: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence
Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate
Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7
Nucleus Detect are trademarks or registered trademarks of Genomic
Health, Inc. Exact Sciences and Cologuard are trademarks or
registered trademarks of Exact Sciences Corporation.
About Cologuard
Cologuard was approved by the FDA in August 2014, and results
from Exact Sciences' prospective 90-site, point-in-time,
10,000-patient pivotal trial in adults 50 years of age or older
were published in the New England Journal of Medicine in
March 2014. Cologuard is included in the American Cancer
Society's (2018) colorectal cancer screening guidelines and the
recommendations of the U.S. Preventive Services Task Force (2016)
and National Comprehensive Cancer Network (2016). Cologuard is
indicated to screen adults 45 years of age and older who are at
average risk for colorectal cancer by detecting certain DNA markers
and blood in the stool. Do not use Cologuard if you have had
precancer, have inflammatory bowel disease and certain hereditary
syndromes, or have a personal or family history of colorectal
cancer. Cologuard is not a replacement for colonoscopy in high risk
patients. Cologuard performance in adults ages 45-49 is estimated
based on a large clinical study of patients 50 and older. Cologuard
performance in repeat testing has not been evaluated.
The Cologuard test result should be interpreted with caution. A
positive test result does not confirm the presence of cancer.
Patients with a positive test result should be referred for
diagnostic colonoscopy. A negative test result does not confirm the
absence of cancer. Patients with a negative test result should
discuss with their doctor when they need to be tested again.
Medicare and most major insurers cover Cologuard. For more
information about Cologuard, visit www.cologuard.com. Rx
Only.
Forward-Looking Statements
This news release contains
forward-looking statements concerning our expectations,
anticipations, intentions, beliefs or strategies regarding the
future. These forward-looking statements are based on
assumptions that we have made as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions and events to differ materially from
those anticipated. You should not place undue reliance on
forward-looking statements. Risks and uncertainties that may affect
our forward-looking statements are described in the Risk Factors
sections of our most recent Annual Report on Form 10-K and any
subsequent Quarterly Reports on Form 10-Q, and in our other reports
filed with the Securities and Exchange Commission. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
i American Cancer Society. Key Statistics for
Colorectal Cancer.
https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html.
Accessed May 18, 2021.
ii Piscitello A, Edwards DK. Estimating the
screening-eligible population size, aged 45 to 74, at average risk
to develop colorectal cancer in the
United States. Cancer Prev
Res. 2020;13(5):443-448.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/modeling-data-showed-cologuard-was-superior-to-fecal-immunochemical-test-fit-on-cost-effectiveness-and-colorectal-cancer-incidence-and-mortality-301296733.html
SOURCE EXACT SCIENCES CORP